XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.25.3

Reinsurance (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Reinsurance Disclosures [Abstract] |
Schedule of Effects of Reinsurance | The following table summarizes the quota share reinsurance coverage that Essent Re has provided to Essent Guaranty for the respective NIW periods:
NIW Period |  | Ceding Percentage
January 1, 2025 to Present |  | 50%
January 1, 2021 to December 31, 2024 |  | 35%
Prior to January 1, 2021 |  | 25%
The effect of reinsurance on net premiums written and earned is as follows:
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
(In thousands) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Net premiums written: |  |  |  |  |  |  |  |
Direct |  | $ | 280,796 |  |  | $ | 277,754 |  |  | $ | 828,062 |  |  | $ | 819,595 |
Ceded (1) |  | (38,968) |  |  | (34,789) |  |  | (106,475) |  |  | (92,524) |
Net premiums written |  | $ | 241,828 |  |  | $ | 242,965 |  |  | $ | 721,587 |  |  | $ | 727,071 |
Net premiums earned: |  |  |  |  |  |  |  |
Direct |  | $ | 285,300 |  |  | $ | 283,725 |  |  | $ | 847,464 |  |  | $ | 838,941 |
Ceded (1) |  | (38,968) |  |  | (34,789) |  |  | (106,475) |  |  | (92,524) |
Net premiums earned |  | $ | 246,332 |  |  | $ | 248,936 |  |  | $ | 740,989 |  |  | $ | 746,417 |
(1)Net of profit commission. The following table summarizes Essent Guaranty's quota share reinsurance agreements as of September 30, 2025:
QSR Agreement |  | Coverage Period |  | Ceding Percentage
QSR-2019 |  | September 1, 2019 - December 31, 2020 |  | (1)
QSR-2022 |  | January 1, 2022 - December 31, 2022 |  | 20%
QSR-2023 |  | January 1, 2023 - December 31, 2023 |  | 17.5%
QSR-2024 |  | January 1, 2024 - December 31, 2024 |  | 15%
QSR-2025 |  | January 1, 2025 - December 31, 2025 |  | 25%
_______________________________________________________________________________ (1)Under QSR-2019, Essent Guaranty cedes 40% of premiums on singles policies and 20% on all other policies.
Schedule of Coverages and Retentions | The following table summarizes Essent Guaranty's excess of loss coverages and retentions provided by insurance linked notes as of September 30, 2025:
(In thousands) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deal Name | Vintage |  | Remaining Insurance in Force |  | Remaining Risk in Force |  |  |  | Remaining Reinsurance in Force |  |  |  |  | Remaining First Layer Retention |  |  |  |  |  | Optional Termination Date
Radnor Re 2021-1 | Aug. 2020 - Mar. 2021 |  | $ | 19,739,682 |  |  | $ | 5,468,250 |  |  |  |  | $ | 114,739 |  |  |  |  |  | $ | 276,517 |  |  |  |  |  |  | June 26, 2028
Radnor Re 2021-2 | Apr. 2021 - Sep. 2021 |  | 25,483,612 |  |  | 7,221,803 |  |  |  |  | 209,214 |  |  |  |  |  | 273,314 |  |  |  |  |  |  | November 25, 2027
Radnor Re 2022-1 | Oct. 2021 - Jul. 2022 |  | 25,108,189 |  |  | 6,942,042 |  |  |  |  | 140,407 |  |  |  |  |  | 295,115 |  |  |  |  |  |  | September 25, 2028
Radnor Re 2023-1 | Aug. 2022 - Jun. 2023 |  | 25,659,356 |  |  | 7,054,365 |  |  |  |  | 227,315 |  |  |  |  |  | 274,987 |  |  |  |  |  |  | July 25, 2028
Radnor Re 2024-1 | Jul. 2023 - Jul. 2024 |  | 26,433,237 |  |  | 7,318,400 |  |  |  |  | 282,240 |  |  |  |  |  | 255,938 |  |  |  |  |  |  | September 25, 2029
Total |  |  | $ | 122,424,076 |  |  | $ | 34,004,860 |  |  |  |  | $ | 973,915 |  |  |  |  |  | $ | 1,375,871 |  |  |  |  |  |  |
The following table summarizes Essent Guaranty's excess of loss reinsurance coverages and retentions provided by panels of reinsurers as of September 30, 2025:
(In thousands) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deal Name | Vintage |  | Remaining Insurance in Force |  | Remaining Risk in Force |  |  |  | Remaining Reinsurance in Force |  |  |  |  | Remaining First Layer Retention |  |  |  |  |  | Optional Termination Date
XOL 2019-1 | Jan. 2018 - Dec. 2018 |  | $ | 3,917,343 |  |  | $ | 1,034,525 |  |  |  |  | $ | 76,144 |  |  |  |  |  | $ | 241,999 |  |  |  |  |  |  | February 25, 2026
XOL 2020-1 | Jan. 2019 - Aug. 2019 |  | 5,062,931 |  |  | 1,340,666 |  |  |  |  | 29,152 |  |  |  |  |  | 210,860 |  |  |  |  |  |  | January 25, 2027
XOL 2022-1 | Oct. 2021 - Dec. 2022 |  | 57,047,820 |  |  | 15,687,589 |  |  |  |  | 141,992 |  |  |  |  |  | 480,893 |  |  |  |  |  |  | January 1, 2030
XOL 2023-1 | Jan. 2023 - Dec. 2023 |  | 33,592,906 |  |  | 9,329,166 |  |  |  |  | 36,627 |  |  |  |  |  | 361,520 |  |  |  |  |  |  | January 1, 2029
XOL 2024-1 | Jan. 2024 - Dec. 2024 |  | 37,239,040 |  |  | 10,243,450 |  |  |  |  | 58,005 |  |  |  |  |  | 330,808 |  |  |  |  |  |  | January 1, 2030
XOL 2025-1 | Jan. 2025 - Dec. 2025 |  | 33,292,085 |  |  | 8,918,226 |  |  |  |  | 62,428 |  |  |  |  |  | 265,700 |  |  |  |  |  |  | January 1, 2031
Total |  |  | $ | 170,152,125 |  |  | $ | 46,553,622 |  |  |  |  | $ | 404,348 |  |  |  |  |  | $ | 1,891,780 |  |  |  |  |  |  |
Schedule of VIE Assets and Total Maximum Exposure to Loss | The following table presents total assets of each Radnor Re special purpose insurer as well as our maximum exposure to loss associated with each Radnor Re entity, representing the fair value of the embedded derivatives, using observable inputs in active markets (Level 2), included in other assets (other accrued liabilities) on our condensed consolidated balance sheet and the estimated net present value of investment earnings on the assets in the reinsurance trusts, each as of September 30, 2025:
|  |  |  | Maximum Exposure to Loss
(In thousands) |  | Total VIE Assets |  | On - Balance Sheet |  | Off - Balance Sheet |  | Total
Radnor Re 2021-1 Ltd. |  | $ | 114,739 |  |  | $ | (5,637) |  |  | $ | 7 |  |  | $ | (5,630) |
Radnor Re 2021-2 Ltd. |  | 209,214 |  |  | (6,301) |  |  | 32 |  |  | (6,269) |
Radnor Re 2022-1 Ltd. |  | 140,407 |  |  | (403) |  |  | 23 |  |  | (380) |
Radnor Re 2023-1 Ltd. |  | 227,315 |  |  | 56 |  |  | 40 |  |  | 96 |
Radnor Re 2024-1 Ltd. |  | 282,240 |  |  | 35 |  |  | 62 |  |  | 97 |
Total |  | $ | 973,915 |  |  | $ | (12,250) |  |  | $ | 164 |  |  | $ | (12,086) |

X
- Definition Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479838/944-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479032/944-605-50-1 + Details
Name: | us-gaap_EffectsOfReinsuranceTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ReinsuranceDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of risk undertaken originally by insurer that is not ceded to reinsurer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479838/944-20-50-3 + Details
Name: | us-gaap_ReinsuranceRetentionPolicyTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-9 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-6 + Details
Name: | us-gaap_ScheduleOfVariableInterestEntitiesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration